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Background: Ovarian cancer is immunogenic and residual tumor volume after surgery is known to be prognostic.
Ovarian cancer often follows a recurring-remitting course and microscopic disease states may present ideal
opportunities for immune therapies. We sought to establish the immune profile of a murine model of ovarian
cancer that allows in vivo tumor imaging and the quantitation of microscopic disease.
Results and Discussion: Baseline imaging and weight measurements were taken within 1 and 2 weeks after
intraperitoneal tumor injection, respectively. Significantly higher photons per second from baseline imaging were first
observed 5 weeks after tumor cell injection (p < 0.05) and continued to be significant through 8 weeks after injection
(p < 0.01), whereas a significant increase in weight above baseline was not observed until day 56 (p < 0.0001).
Expression of luc2 in ID8 cells did not alter the cellular immune microenvironment of the tumor. FOXP3+ T cells were
more likely to be detected in the intraepithelial compartment and CD4+ T cells in the stroma as compared to CD3+ T
cells, which were found equally in stroma and intraepithelial compartments.
Conclusions: Use of an intraperitoneal tumor expressing a codon-optimized firefly luciferase in an immunocompetent
mouse model allows tumor quantitation in vivo and detection of microscopic tumor burdens. Expression of this foreign
protein does not significantly effect tumor engraftment or the immune microenvironment of the ID8 cells in vivo and
may allow novel immunotherapies to be assessed in a murine model for their translational potential to ovarian cancers
in remission or minimal disease after primary cytoreductive surgery or chemotherapy.
Methods: Mouse ovarian surface epithelial cells from C57BL6 mice transformed after serial passage in vitro were
transduced with a lentiviral vector expressing a codon optimized firefly luciferase (luc2). Cell lines were selected and
luc2 expression functionally confirmed in vitro. Cell lines were intraperitoneally (IP) implanted in albino C57BL/6/
BrdCrHsd-Tyrc mice and albino B6(Cg)-Tyrc-2 J/J mice for serial imaging. D-luciferin substrate was injected IP and
tumors were serially imaged in vivo using a Xenogen IVIS. Tumor take, weights, and luminescent intensities were
measured. Immunohistochemistry was performed on tumors and assessed for immune infiltrates in stromal and
intraepithelial compartments.
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The ability of the immune system to recognize and re-
spond to ovarian cancers has been known to be import-
ant in prognosis [1,2]. This observation has sparked
much interest in applying immune therapies and vac-
cines for the treatment of this malignancy, however, the
promise of immune therapy has yet to be realized in
ovarian cancer patients despite a number of approaches
taken to model the disease in mice. Mouse models for
ovarian cancer may have more success in translational
oncology if they can replicate the immune microenvir-
onment and allow quantitation of low tumor volumes,
two factors that are known to impact outcomes in hu-
man disease. The presence of intratumoral T cells in
ovarian cancer is an independent prognostic factor for
progression free survival (PFS) and overall survival (OS)
by multivariate analysis and underscores the specific
importance of T-cells [1-7]. Regulatory T cells, another
subset of T cells that can modulate immune responses and
maintain tolerance to self-antigen, have been shown to
predict poor patient survival in ovarian cancer [2,8]. For
advanced ovarian cancers, tumor volume continues to be
an important factor in prognosis, where patients who
achieve microscopic residual have a 34 months median
overall survival advantage over those who have even
0.1 cm macroscopic disease after cytoreductive surgery [9].
Some of the earliest attempts to model ovarian cancer
in mice involved the implantation of human tumor tis-
sue, subcutaneously, in immunodeficient mice [10]. This
allowed the direct measurement of external tumors but
did not replicate the location or important immune in-
teractions. More recently, human tumor xenografts have
been successfully implanted orthotopically in NOD-scid
immunodeficient mice [11-13]. The development of ef-
fective mouse models to study ovarian cancer has also
been hampered by an incomplete understanding of the
molecular events that lead to carcinogenesis. A number
of genetically induced murine models have been devel-
oped that exploit mutations that lead to loss of expres-
sion of tumor suppressor genes and overexpression of
oncogenes, individually and in combination, through the
use of conditional deletion and expression techniques
directed to the murine reproductive tract [14-16]. Tissue
specific promoters have also been utilized to focus ex-
pression of oncogenes in the murine ovary during devel-
opment, but these efforts were insufficient to transform
ovarian surface epithelium, inhibited reproductive func-
tion, and/or introduced oncoproteins such as T antigen,
which have no known role in ovarian carcinogenesis
[17-19]. While a sequence of molecular and cellular
events has been shown to lead to tumor progression in
syngeneic mouse models of ovarian cancer [20], even
high grade serous ovarian cancers in humans exhibit a
great degree of heterogeneity, and carcinogenesis cannotyet be attributed a defined sequence of mutational events
[21], so it is unclear how closely genetically induced mur-
ine models would replicate human disease. Application of
chemical carcinogens such as 7,12-dimethylbenzanthra-
cene (DMBA) have been used to induce cancers of the re-
productive tract in mice with very low efficiency [22].
When these efforts were attempted in rats, success rates
increased to 50%, but it also induced epithelial cancers of
the endometrium and cervix [23]. However, chemical car-
cinogens have yet to be definitively associated with human
ovarian carcinogenesis. Mouse ovarian surface epithelial
cells undergo transformation after serial passages in vitro
and have represented a syngeneic and immunocompetent
mouse model [24]. The intraperitoneal location of these
more recent approaches to modeling ovarian cancer in
mice raises the same issues seen human ovarian cancer:
tumor quantitation and detection of low volume disease.
Murine ovarian tumors have been previously imaged
in vivo using luciferase [25-27]. We sought to evaluate
this approach when it is enhanced to use a codon-
optimized protein and mutant mouse strains that permit
improved transmission of light from intraperitoneal tu-
mors. Use of these modifications has been reported to
allow detection in vivo to the level of 10 cells in albino
mice [28]. It is not known whether the optimized ex-
pression of a xeno-antigen or use of mutant C57BL6
mice will alter tumor engraftment of this mouse model
or how quantitation of these tumors will track with ex-
ternal measures. It is also unknown whether the expres-
sion of xeno-antigen will alter the intraperitoneal tumor
microenvironment potentially eliciting a shift from im-
munosuppressive to inflammatory.
Materials and Methods
Lentiviral infection of ID8 with luciferase vector and cell
line selection
ID8 cells, ovarian surface epithelial cells derived from
the C57B6 mice (obtained from K. Roby, University of
Kansas) [24], were plated at 3x105 cells per well (6-well
plate; Corning, Inc.) and incubated overnight at 37°C/5%
CO2. Media consisted of Dulbecco’s Modification of Ea-
gle’s Medium w/L-glutamine (DMEM; Corning Inc.), 4%
fetal bovine serum (FBS; Gemini), 0.09 mg/ml penicillin-
streptomycin (Corning, Inc.), and 1× insulin/transferrin/
selenium (ITS; Gibco). Cells were infected with 2 mL/
well pLentiIII-Luc2 viral vector supernatant (Applied
Biological Materials Inc.) in the presence of 8 μg/ml
polybrene (EMD Millipore Corporation). After overnight
incubation at 37°C/5% CO2, the viral supernatant and
media with polybrene were removed and the plate was
washed with PBS prior to the addition of warmed media.
Cells were cultured in growth media for 72 hours and
then placed under drug selection with 1 μg/mL puro-
mycin, added daily (Invitrogen). Colonies were selected
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(Invitrogen) and grown to confluence in 6 well plates.
Cells were then trypsinized, spun, and suspended to a con-
centration of 5×104 cells/100 μl. One hundred μl of cells
were added per well in a white 96-well plate (EMD Milli-
pore Corporation) and equal volume of 3000 μg/ml d-
luciferin was added immediately before reading. Lines
were selected based maximal relative light units after
addition of substrate as a measure of functional luciferase
expression (Additional file 1: Figure S1).
Mice
C57/BL/6/BrdCsHsd-Tyrc (Harlan Laboratories) and B6
(Cg)-Tyrc-2 J/J mice (Jackson Laboratories) were ac-
quired and maintained under standard pathogen-free
conditions at the University of Washington. Both C57/
BL/6/BrdCsHsd-Tyrc and B6(Cg)-Tyrc-2 J/J mice con-
tain a mutation in the c(tyrosinase) gene yielding an al-
bino coat and have the H-2b immune haplotype. 6–8
week old female mice were used for this study and
allowed to acclimate for one week in-house prior to
treatment. Blood was collected by orbital bleed, every
two weeks throughout all studies. Mice were directly ob-
served and weighed every 2–3 days after tumor growth
was evident. Mice were euthanized when they exhibited
clinical signs of disease or distress (i.e. cachexia, an-
orexia, or increased respiratory rates), development of
ascites or when tumors began to interfere with normal
bodily functions (i.e. ambulation, eating, drinking, defe-
cating, and urinating). All protocols were approved by
the Institutional Animal Care and Use Committee.
In vivo propagation of ID8-luc2 tumors
Mice were given a 200 μL intraperitoneal injection of
ID8 cells, ranging from one to five million cells per
mouse. With the mouse in the supine position, half the
dose was injected using a 25 gauge needle in the lower
left quadrant and the other half in the lower right quad-
rant. At designated intervals after tumor implant, the
mice were imaged to monitor tumor progression. The
two mouse strains were evaluated with either a low-load
(1×106 cells) or a high-load (5×106 cells) of either a low
(greater than 10,000 relative light units) or high (greater
than 50,000 relative light units) expression luc2 line. A
total of 32 mice were injected with tumors, at 4 mice
per group, as follows for both mouse strains: low-load +
low-expression line, low-load + high-expression line,
high-load + low-expression line, and high-load + high-ex-
pression to select a condition that gave a significant
change in total luminescent flux at 4 weeks (Additional
file 2: Figure S2). All subsequent studies were performed
using 5 mice per treatment group with Harlan C57BL/6
mice with the high expression luc2 line at 5×106 cells/
mouse. Significance was determined using repeatedmeasures ANOVA for weights. All time points were
compared to the earliest time point of 14 days or 2 weeks
after tumor cell injection.
Bioluminescence/Imaging
Bioluminescent images were taken with Xenogen IVIS
using D-luciferin, (In Vivo Imaging Solutions) as previ-
ously described [26]. Images were normalized using Liv-
ing Image software (PerkinElmer) with a minimum and
maximum radiance of 5×105 and 2.5×106 photons/sec,
respectively. Maximum luminescent intensity and total
flux in photons per second were calculated and reported
for each mouse’s abdominal region in photons/sec. Sig-
nificance was determined using one way Anova for lumi-
nescence. All time points were compared to the earliest
time point of 14d or 2 weeks after tumor cell injection.
Successful engraftment of intraperitoneal tumors was
defined as 5×105 photons/sec. This value was based on
prior studies which demonstrated that failure to achieve
more than 105 photons/sec bioluminescent emission
correlated with rejection of implanted tumor [29].
Enzyme-linked immunosorbent assay
Blood samples were centrifuged and sera collected for
analysis. Serum antibodies to luciferase were assessed
using an indirect ELISA [30]. Alternate columns on
Immulux HB plates (Dynex Technologies, Inc.) were
coated with 5 μg/mL firefly luciferase (Abcam) in car-
bonate buffer, determined optimal by a checkerboard ti-
tration. Serially diluted, purified human IgG (Sigma)
provided a standard curve. Plates were incubated over-
night at 4°C followed by a one hour block with 1X PBS/
5% bovine serum albumin (BSA; Fitzgerald Industries
International) at room temperature. After washing three
times with ELISA wash buffer: 1XPBS/ 0.1% Tween
(Thermo Fisher Scientific Inc), serum samples obtained
by orbital bleeding from mice with tumors expressing
luc2 were diluted 1:100 in 1XPBS/1% BSA, and incu-
bated for an hour. A positive control of rabbit anti-
firefly luciferase 36 μL diluted in 414 μL (Abcam) and
negative control of normal mouse serum 10 uL diluted
in 115 μL 1XPBS/1% BSA were run on every plate.
Plates were re-run if positive control value less than 20
fold of the negative control value as well as if the nega-
tive controls were more than 5% above background.
Plates were washed three times with wash buffer, then
1:100,000 secondary antibody of goat anti human, mouse
or rabbit-IgG-horseradish peroxidase (HRP; SigmaAldrich)
conjugates was added to control, standard curve, and ex-
perimental wells and incubated for 45 minutes. After wash-
ing again, plates were developed with TMB (KPL) and the
reaction was read at an optical density of 640 nm until the
well containing the standard concentration of 0.078 μg/mL
reached 0.3 OD. The reaction was stopped with an equal
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each serum dilution was calculated as the OD450 of
antigen-coated well minus the OD450 of carbonate buffer
coated wells. Values in μg/mL for each OD450 were calcu-
lated from the log-log equation of the line for the standard
curve on each plate as plotted by Softmax Pro 5.3
(Molecular Devices Corp). A sample was defined as
positive if the value was greater than 2 standard devia-
tions above the mean value of controls, or mice implanted
with the parental ID8 cell line (n = 10). Intra-assay and
inter-assay coefficients of variation were 8% and 12.5% re-
spectively (8 plates evaluated).
Immunohistochemistry
Staining was performed on a Leica Bond Automated
Immunostainer. Frozen sections were chilled in acetone
and washed in PBS prior to antigen retrieval at 100°C
for 10–20 minutes. Slides were then blocked with 10%
normal goat sera in TBS for 10 minutes followed by in-
cubation with Rat anti-mouse CD3 (AbD Serotec, Cat.
No. MCA1477, 1.0 mg/mL) at 1:500 dilution, anti-mouse
FOXP3 (eBioscience, Cat. No. 14–5773, 0.5 mg/ml) 1:250,
anti-mouse CD4 (BD Pharmingen, Cat. No. 550278,
62.5 μg/ml) 1:500, or rat IgG isotype control (BDFigure 1 Bioluminescent imaging detects tumor prior to significant weight
at 2 (A) and 4 weeks (B) after injection. Mice are placed in the same positio
after tumor cell injection (x-axis), n = 32. (D) Average luminescent units at 2, 4,
**p < 0.01, ****p < 0.0001.Pharmingen, Cat No. 553986, Lot No. MO53508,
0.5 mg/mL) 1:500 dilution in Bond primary antibody dilu-
ent (Leica) for 30 minutes at room(Leica) for 30 minutes
at room temperature. Secondary antibody, rabbit anti-rat
IgG (Vector Laboratories Inc., Cat No AI-4001, 0.5 mg/
mL; diluted 1:300 in 5% NGS/1XTBS) was incubated for
8 minutes at room temperature. Sections were then incu-
bated with 8 μg/mL goat anti rabbit poly-HRP polymer
secondary detection (Leica) for 8 minutes at room
temperature, followed by Leica Bond Mixed Refine DAB
substrate detection for 10 minutes at room temperature
(Leica). After washing with diH2O the sections were coun-
ter stained with Mayer hematoxylin solution (Newcomer
Supply, Cat No. 12013) dehydrated through 100%, cleared
in xylene and mounted with synthetic resin mounting
medium and #1.5 coverslip. Quantification of tumor infil-
trating lymphocytes (TILs) was performed as previously
described using H&E staining to identify stromal and
intraepithelial sections and reported as a percentage of
positively stained cells for CD3, CD4, and FOXP3 [2].
Flow cytometry
Splenocytes and TILs were analyzed by flow cytometry.
Lymphocytes from tumor and spleens were isolated aschange Representative bioluminescent imaging of ID8 Luc2 implant
ns for both images. (C) Average weight of mice at 2, 4, 5, and 8 weeks
5, and 8 weeks after tumor cell injection (x-axis), n = 32. *p < 0.05,
Figure 2 Development of endogenous luc2 specific IgG antibodies
did not impact tumor growth. (A) Serum firefly luciferase specific IgG
μg/mL (y-axis) for ID8 luc2 mice, over time in weeks (x-axis). Bars
represent mean and SEM. n = 16 (B) Bioluminescent imaging of ID8
Luc2 mice at 4 and 6 weeks post tumor implant. Serum firefly luciferase
specific IgG μg/mL (y-axis) compared to matched bioluminescent flux
(x-axis). Linear regression line shown in blue. (n = 32).
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formed as shown previously and anti-mouse CD16/CD32
antibody (BD Pharmingen) was used to block nonspecific
binding [33]. The following fluorochrome-conjugated anti-
bodies were used in 2×106 cells: 0.4 μg CD45 (eBioscience,
clone #30-F11), 0.4 μg CD3 (BD Pharmingen, clone
#145-2C11), 0.4 μg CD4 (BioLegend, clone #GK1.5),
0.4 μg CD8 (eBioscience, clone #53-6.7), 0.4 μg CD11b
(eBioscience clone #M1/70), 0.4 μg GR-1 (BD Pharmin-
gen clone #RB6-8C5), and 1 μg Foxp3-Alexa488
(eBioscience, clone # FJK.16 s). Stained cells were
acquired with FACS Canto flow cytometer (BD Bio-
science) and 1×106 to 2×106 cells were analyzed with
FlowJo software (Tree Star Inc.). Results are reported as
total percentage of a cell population or ratio of cell
quantities, as indicated.
Statistical analysis
Graphs and statistical comparisons were completed
using GraphPad Prism v5.04 software. Unpaired t-tests
and one-way ANOVA were used. Significance was de-
fined as p < 0.05 for all statistical tests.
Results
Bioluminescent imaging is a more sensitive indication of
tumor growth than weight gain in ovarian cancer mouse
models
We wished to examine whether factors such as number
of tumor cells injected IP, choice of C57Bl6 mutant
strains, and expression level of luc2, a codon-optimized
firefly luciferase, in a selected line impacted tumor de-
tection and engraftment rates. We hypothesized that use
of bioluminescent imaging would enhance detection of
small volume tumors in advance of external measures
and that expression of a foreign antigen, luc2, would not
impair engraftment. In order to determine if a lower
number of implanted tumor cells could still be detect-
able by bioluminescence and still have a high engraft-
ment rate, we injected mice with IP tumors of the ID8
cells with high expression of luc2 at both the reported
number used in the parental line, 5×106 and 1×106 cells.
81% of mice injected with 1×106 cells had detectable
tumor by 2 weeks after implantation. All mice injected
with 5×106 tumor cells had detectable tumors by bio-
luminescent imaging 2 weeks after implantation. Serial
images showed a distribution of bioluminescent tumor
approximating progressive metastatic peritoneal carcin-
omatosis. Compared to baseline imaging and weight
measurements taken within 1 and 2 weeks after intra-
peritoneal tumor injection, significantly higher photons
per second from baseline imaging were first observed
5 weeks after tumor cell injection (p = 0.0144) and contin-
ued to be significant through 8 weeks after injection
(p = 0.002), whereas a significant increase in weight abovebaseline was not observed until day 56 (p < 0.0001;
Figure 1).
We also examined 2 selected lines of ID8-luc2 cells, a
low expression line A (n = 16) and a high expression line
B (n = 16) to assess if high levels of overexpression of a
foreign protein such as luc2 will effect tumor engraft-
ment. No significant change between the two lines was
seen at 2, 4, and 6, weeks, by one way ANOVA (p = 0.16;
Additional file 2: Figure S2A). In order to optimize light
transmission we also tested the selected ID8-luc2 lines
in two C57Bl6 based mouse strains with white coats
from 2 vendors. There were no significant differences
seen between these groups and tumors were visualized
at 2 weeks with both strains (p > 0.05; Additional file 2:
Figure S2A).
Development of endogenous luc2 specific IgG antibodies
did not impact tumor growth
We hypothesized that expression of a foreign antigen may
generate autoantibodies, but that these may not be suffi-
cient to cause tumor regression, since autoantibodies
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not correlate with overall survival in 2 out of 3 antigens
studied in ovarian cancer patients [34]. Serum antibodies
specific for firefly luciferase were elevated in 3 of 16
(18.75%) tumor bearing mice at 6 weeks after implantation
with 5×106 cells, with a mean +/− SEM of 12.6 μg/mL
+/− 6.2, (range: 0.17 to 93.1) using the two cell lines and
both mouse strains (Figure 2A). The proportion of mice
with serum antibodies to luciferase at a concentration
greater than the mean and SEM were 2 of 16 (6.25%) on
week 4, 3 of 16 (18.75%) on week 6, and 2 of 16 (12.5%)
on week 8. These elevated levels were not significantly dif-
ferent by one way ANOVA, showing that development of
antibodies did not vary significantly by time of exposure
to luciferase (Figure 2A). Linear regression analysis per-
formed on serum antibody levels and total biolumines-
cent flux did not show a significant correlation or a
significantly non-zero slope (R2 = 0.05411; p = 0.20;
Figure 2B). The higher expressing line induced a posi-
tive antibody response at earlier time points, as early as
4 weeks, but serum antibody responses were ultimately
detected in both mouse strains, using both high and
low expressing lines, and both high and low cell num-
bers by eight weeks (Additional file 2: Figure 2B).Expression of luc2 in ID8 cells does not alter the cellular
immune microenvironment of the tumor
The percentage of tumor infiltrating CD3+ CD45+ posi-
tive lymphocytes was not significantly different in the luc2
line compared to the parental line (p = 0.914; Figure 3A).Figure 3 Expression of codon-optimized firefly luciferase in ID8 cells does
in ID8 Luc2 (Dark Gray, n = 6) compared to ID8 parental line (White bar
post tumor implant. (B) CD8 T-cell populations, (C) CD4 T-Cell populations,
suppressor cells or MDSC’s. All cell subtypes were CD45+ gated. Horizontal baThere was also no significant differences seen in CD8+
populations infiltrating tumor (p = 0.4002) or in the CD4+
population (p = 0.8499; Figure 3B and C). The expression
of luciferase also did not significantly alter the levels of
regulatory T cells, FOXP3+ CD4+ cells (p = 0.3157;
Figure 3D) or MDSC (p = 0.9108; Figure 3E) in tumors.
There were no significant differences in these same cell
populations in ascites or splenocytes (all p values >0.05) in
mice implanted with ID8 luc2 tumors compared to the
parental line, with the exception of an elevation in MDSC
seen in the splenocytes of mice bearing the parental ID8
tumors compared to mice bearing the ID8 tumors ex-
pressing luc2 (p = 0.02).FOXP3+ T cells were more likely to be detected in the
intraepithelial compartment and CD4+ T cells in the
stroma as compared to CD3+ T cells, which were found
equally in stroma and intraepithelial compartments
Immunohistochemical staining of ID8-luc2 tumors iden-
tified infiltration of CD3+ T cells (Figure 4A) and
FOXP3+ cells (Figure 4B). No significant difference in
percentage of positively stained CD3+ TILs was seen in
the stroma compared to intraepithelial compartment.
A significantly higher percentage of CD4+ TILs were
detected in the stromal compartment compared to the
intraepithelial compartment (p < 0.0001). Positively staining
intraepithelial FOXP3+ were also significantly increased
compared to stromal FOXP3+ (p < 0.0001; Figure 4C).
Representative photomicrographs of tumor infiltrates are
shown in Figure 4D.not alter cellular immune microenvironment (A) CD3 T cells (y-axis)
s, n = 8) in mouse tumor, ascites, and spleen (x-axis) at 12–15 weeks
(D) FOXP3 T-regulatory cells populations, (E) CD11bGr1 myeloid derived
rs are SEM.
Figure 4 FOXP3+ T cells were more likely to be detected in the intraepithelial compartment and CD4 T cells in the stroma compared to
CD3 T cells, which were found equally in stroma and intraepithelial compartments (A) CD3 immunohistochemistry (i) compared to Rat
IgG isotype control (ii). (B) FOXP3 T-cell immunohistochemistry (i) compared to Rat IgG isotype control (ii). (C) Box and whisker plot showing
percent CD3 (n = 10), CD4 (n = 10), and FOXP3 (n = 10) cells from immunohistochemistry compared between stromal and intraepithelial sections.
(D) Representative images of stromal and intraepithelial lymphocyte infiltration in the stromal (i) and intraepithelial (ii) compartments by H and E
(a), CD3 (b), CD4 (c), and FoxP3 (d).
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Mouse models for ovarian cancer that can recapitulate
the immune microenvironment will allow translational
testing of immune based therapies. Ovarian cancer is an
immunogenic tumor and the phenotype of the immune
microenvironment has been shown to impact prognosis
in a number of studies. The presence of CD3+ T cell infil-
trates, and the homing of this infiltrate to the intraepithelial
compartment, has been shown to be prognostic for im-
proved survival by multivariate analysis [1-3,35]. Conversely,
the development of immunomodulatory responses
such as the recruitment of regulatory T cells and a lowratio of cytotoxic CD8+ to regulatory T cells has been
shown to predict poor patient survival [2,8]. Systemic
immune responses have also been shown to be import-
ant in survival [36].
Two common proteins used to visualize tumor cells
in vivo are the green fluorescent protein (GFP) derived
from the jellyfish Aequorea victoria, and luciferase derived
from the firefly. Expression of foreign proteins in cancer
lines must be done with caution especially in those can-
cers where knowledge of the immune interactions have
been shown to effect clinical outcomes such as in ovarian
cancer because expression of a xeno-protein may be
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pression in human cancer cells results in significant oxida-
tive stress and can enhance cytotoxicity by upregulating
total glutathione [37]. GFP has also been reported to pro-
mote caspase 3 activation and apoptosis [38]. Luciferase
has been used successfully in vivo without negatively
impacting tumor growth in immunocompetent mouse
models of ovarian cancer [25,26]. We have shown that a
codon-optimized version of this protein in mutant mice
with an albino coat also propagates well in vivo. Codon-
optimization and removal of cryptic splice sites has been
shown to enhance the transmission of light and allows de-
tection at the 10 cell level in albino mice [28].
Luciferase is known to be weakly immunogenic in
Balb/c mice [39]. We have also shown immunogenicity
of ID8 cells expressing luc2 in the C57Bl/6 immune
background. In this model and this immune background,
expression of luc2 does not alter the immune profile in
tumor, ascites, or spleen in tumor bearing mice with the
possible exception of MDSC, which is of uncertain sig-
nificance since MDSC have been reported to change
over time in this model [40]. Despite the stimulation of
the immune system seen with the expression of luc2 in
the transduced tumor line, engraftment rates and tumor
growth did not differ.
The quantitation of CD3 T cells and CD4 T cells in the
stromal and intraepithelial compartments also reflects
what has been observed in human ovarian cancer. Sato
and colleagues reported that CD3 T cells and CD4 T cells
are found in higher numbers in the stromal compartments
with increases in the means and medians of 5 to 6 fold
and 8 to 9 fold for CD3 and CD4 respectively [2]. We saw
the same trend in both CD3 and CD4 in when we quanti-
tated stromal and intraepithelial staining of ID8 cells using
the same techniques, although only CD4 was statistically
significant in our more limited sample size. Although Sato
and colleagues did not directly report stromal or intrae-
pithelial FOXP3 staining, they attributed the negative sur-
vival impact of CD4 T cells to regulatory T cells. We see a
significant increase in intraepithelial FOXP3 staining for
the ID8 tumor compared to the stromal compartment,
despite a decrease in CD4 staining suggesting enrichment
of the regulatory T cells in the intraepithelial compart-
ment. This is congruent with recognition of the import-
ance of CD8 in the intraepithelial compartment in
prognosis of human ovarian cancer.
Conclusions
We conclude that use of a codon-optimized firefly lucif-
erase expressed in ID8 cells in albino mice represents an
immunocompetent model of ovarian cancer that main-
tains the tumor-host interactions seen without expres-
sion of the reporter gene. Humoral immune responses
against a xeno-transgene do not correlate with tumorrejection and the tumor microenvironment is not al-
tered. This system may allow effective preclinical testing
of novel immune therapies and vaccines for ovarian can-
cer in a mouse model that replicates the immune micro-
environment. The ability to detect and quantitate
microscopic disease in vivo will also allow the study of
strategies targeting optimally cytoreduced or clinical re-
missions to prevent recurrence.
Additional files
Additional file 1: Figure S1. Selection of transduced luc2 tumor cell lines
Selection of ID8 cell lines transduced with luc2 and tested for expression by
the addition of d-luciferin substrate in vitro compared to parental line. (A)
was selected as a representative low expression line and (B) was selected as
a representative high expression line. Each bar represents a single mean of
4 replicates for a single subline. Error bars represent standard error.
Additional file 2: Figure S2. Comparison of mouse type, cell line, and cell
load (A) Total flux (Y-axis) versus time in weeks (x-axis) for each experimental
group. Experimental groups do not differ significantly. (B) Serum antibody
concentration (Y-axis) versus time in weeks (x-axis) for each experimental
group. Circles denote Luc2 A clone, Squares: Luc2B clone. Filled in shapes
represent a cell load of 1x106 cells/mouse. Open shapes represent a cell
load of 5x106 cells/mouse. Four replicates per condition: 2 cell lines (A
-low expression or B -high expression), 2 cell loads (1x106 cells/mouse
or 5x106 cells/mouse), and 2 mouse types C57/BL/6/BrdCsHsd-Tyrc
(Harlan Laboratories) or B6(Cg)-Tyrc-2 J/J mice (Jackson Laboratories)
Total mice: n = 32.
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